// App-Quantinova.ai

BSH2020‐OR‐019 : Tailoring treatment for patients with newly diagnosed high‐risk myeloma – feasibility results of the UKMRA OPTIMUM (MUKnine) trial

Researchers

Presenter

  • M. Jenner

Principal Investigators

  • A. Hall

  • A. Sherborne

  • K. Walker

  • K. Sharp

  • K. Bowles

  • M. Garg

  • S. Ellis

  • G. Jackson

  • L. Flanagan

  • M. Drayson

  • R. DeTute

  • R. Owen

  • G. Pratt

  • G. Cook

  • S. Brown

  • M. Kaiser

Medical Centers

  • University Hospital Southampton NHS Trust,Southhampton,Regno Unito

  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • The Institute of Cancer Research, London, UK

  • Norwich Medical School, University of East Anglia

  • Norfolk & Norwich UniversityHospitals, Norfolk, UK

  • Leicester University Hospital, Leicester

  • Newcastle University, Newcastle Upon Tyne, UK

  • Birmingham University, Birmingham

  • HMDS, Leeds Teaching Hospitals NHS Trust, Leeds

  • University Hospitals Birmingham, Birmingham, UK

  • Leeds Institute for Clinical Trials Research, Leeds

  • Leeds Institute of Cancer and Pathology, Leeds University, Leeds

  • The GI Unit, Royal Marsden Hospital, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Monoclonal gammopathy

Biomarkers

  • Granulin precursor

  • Syndecan-1

  • Monoclonal gammopathy of undetermined significance

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

  • Sparsentan

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved